Literature DB >> 36166152

OCT-Based Biomarkers are Associated with Systemic Inflammation in Patients with Treatment-Naïve Diabetic Macular Edema.

Jingxin Zhou1, Siyuan Song1, Yi Zhang2, Kai Jin3, Juan Ye4.   

Abstract

INTRODUCTION: Diabetic macular edema (DME) is one of the major sight-threatening complications of diabetic retinopathy, which is associated with retinal inflammation. However, it is still unknown whether DME is associated with systemic inflammation. The study aimed to investigate the association between systemic inflammatory and optical coherence tomography (OCT) biomarkers in patients with treatment-naïve center-involving diabetic macular edema (DME) and to further explore the role of systemic inflammation in DME.
METHODS: Medical records including clinical characteristics and ophthalmic examinations were collected from patients with treatment-naïve center-involving DME. Systemic inflammation markers including systemic immune-inflammatory index (SII), neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) were calculated. OCT biomarkers, including intraretinal cyst (IRC) size, disorganization of retinal inner layers (DRIL), external limiting membrane (ELM)/ellipsoid zone (EZ) integrity, retinal hyperreflective foci (HRF), subretinal fluid (SRF) and vitreomacular (VM) status were evaluated manually. Correlation analysis and multivariable linear regression models were used to investigate the relationship between systemic inflammatory markers and OCT biomarkers.
RESULTS: A total of 82 patients with treatment-naïve center-involving DME were included. The number of HRF on OCT was correlated with SII, NLR, and PLR and positively associated with SII (p < 0.001) in both univariate and multivariate linear regression analyses. The differences remained largely the same during subgroup analysis controlling DM duration, SRF, and ELM/EZ integrity. No significant association was observed between other OCT biomarkers and blood inflammatory markers.
CONCLUSION: Retinal HRF in diabetic macular edema is associated with blood inflammatory markers, which supports the theory of HRF's inflammatory nature and emphasizes the important role of inflammation in DME. SII may be a potential marker for DME treatment decisions.
© 2022. The Author(s).

Entities:  

Keywords:  Biomarker; Diabetic macular edema; Inflammation; Optical coherence tomography

Year:  2022        PMID: 36166152     DOI: 10.1007/s40123-022-00576-x

Source DB:  PubMed          Journal:  Ophthalmol Ther


  54 in total

Review 1.  Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets.

Authors:  Arup Das; Paul G McGuire; Sampathkumar Rangasamy
Journal:  Ophthalmology       Date:  2015-04-30       Impact factor: 12.079

Review 2.  Diabetic macular oedema.

Authors:  Gavin S Tan; Ning Cheung; Rafael Simó; Gemmy C M Cheung; Tien Yin Wong
Journal:  Lancet Diabetes Endocrinol       Date:  2016-08-03       Impact factor: 32.069

3.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

4.  Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

Authors:  David M Brown; Ursula Schmidt-Erfurth; Diana V Do; Frank G Holz; David S Boyer; Edoardo Midena; Jeffrey S Heier; Hiroko Terasaki; Peter K Kaiser; Dennis M Marcus; Quan D Nguyen; Glenn J Jaffe; Jason S Slakter; Christian Simader; Yuhwen Soo; Thomas Schmelter; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Carola Metzig; Jean-François Korobelnik
Journal:  Ophthalmology       Date:  2015-07-18       Impact factor: 12.079

5.  Prevalence of diabetic retinopathy in the United States, 2005-2008.

Authors:  Xinzhi Zhang; Jinan B Saaddine; Chiu-Fang Chou; Mary Frances Cotch; Yiling J Cheng; Linda S Geiss; Edward W Gregg; Ann L Albright; Barbara E K Klein; Ronald Klein
Journal:  JAMA       Date:  2010-08-11       Impact factor: 56.272

6.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Authors:  John A Wells; Adam R Glassman; Allison R Ayala; Lee M Jampol; Neil M Bressler; Susan B Bressler; Alexander J Brucker; Frederick L Ferris; G Robert Hampton; Chirag Jhaveri; Michele Melia; Roy W Beck
Journal:  Ophthalmology       Date:  2016-02-27       Impact factor: 12.079

Review 7.  Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings.

Authors:  Tien Y Wong; Jennifer Sun; Ryo Kawasaki; Paisan Ruamviboonsuk; Neeru Gupta; Van Charles Lansingh; Mauricio Maia; Wanjiku Mathenge; Sunil Moreker; Mahi M K Muqit; Serge Resnikoff; Juan Verdaguer; Peiquan Zhao; Frederick Ferris; Lloyd P Aiello; Hugh R Taylor
Journal:  Ophthalmology       Date:  2018-05-24       Impact factor: 12.079

Review 8.  Global prevalence and major risk factors of diabetic retinopathy.

Authors:  Joanne W Y Yau; Sophie L Rogers; Ryo Kawasaki; Ecosse L Lamoureux; Jonathan W Kowalski; Toke Bek; Shih-Jen Chen; Jacqueline M Dekker; Astrid Fletcher; Jakob Grauslund; Steven Haffner; Richard F Hamman; M Kamran Ikram; Takamasa Kayama; Barbara E K Klein; Ronald Klein; Sannapaneni Krishnaiah; Korapat Mayurasakorn; Joseph P O'Hare; Trevor J Orchard; Massimo Porta; Mohan Rema; Monique S Roy; Tarun Sharma; Jonathan Shaw; Hugh Taylor; James M Tielsch; Rohit Varma; Jie Jin Wang; Ningli Wang; Sheila West; Liang Xu; Miho Yasuda; Xinzhi Zhang; Paul Mitchell; Tien Y Wong
Journal:  Diabetes Care       Date:  2012-02-01       Impact factor: 19.112

Review 9.  Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory.

Authors:  Pedro Romero-Aroca; Marc Baget-Bernaldiz; Alicia Pareja-Rios; Maribel Lopez-Galvez; Raul Navarro-Gil; Raquel Verges
Journal:  J Diabetes Res       Date:  2016-09-28       Impact factor: 4.011

Review 10.  The Role of Inflammation in Diabetic Retinopathy.

Authors:  John V Forrester; Lucia Kuffova; Mirela Delibegovic
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.